Literature DB >> 15065127

Immunohistochemical localization of aspartoacylase in the rat central nervous system.

Chikkathur N Madhavarao1, John R Moffett, Roger A Moore, Ronald E Viola, M A Aryan Namboodiri, David M Jacobowitz.   

Abstract

Aspartoacylase (ASPA; EC 3.5.1.15) catalyzes deacetylation of N-acetylaspartate (NAA) to generate free acetate in the central nervous system (CNS). Mutations in the gene coding ASPA cause Canavan disease (CD), an autosomal recessive neurodegenerative disease that results in death before 10 years of age. The pathogenesis of CD remains unclear. Our working hypothesis is that deficiency in the supply of the NAA-derived acetate leads to inadequate lipid/myelin synthesis during development, resulting in CD. To explore the localization of ASPA in the CNS, we used double-label immunohistochemistry for ASPA and several cell-specific markers. A polyclonal antibody was generated in rabbit against mouse recombinant ASPA, which reacted with a single band (approximately 37 kD) on Western blots of rat brain homogenate. ASPA colocalized throughout the brain with CC1, a marker for oligodendrocytes, with 92-98% of CC1-positive cells also reactive with the ASPA antibody. Many cells were labeled with ASPA antibodies in white matter, including cells in the corpus callosum and cerebellar white matter. Relatively fewer cells were labeled in gray matter, including cerebral cortex. No astrocytes were labeled for ASPA. Neurons were unstained in the forebrain, although small numbers of large reticular and motor neurons were faintly to moderately stained in the brainstem and spinal cord. Many ascending and descending neuronal fibers were moderately stained for ASPA in the medulla and spinal cord. Microglial-like cells showed faint to moderate staining with the ASPA antibodies throughout the brain by the avidin/biotin-peroxidase detection method, and colocalization studies with labeled lectins confirmed their identity as microglia. The predominant immunoreactivity in oligodendrocytes is consistent with the proposed role of ASPA in myelination, supporting the case for acetate supplementation as an immediate and inexpensive therapy for infants diagnosed with CD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065127     DOI: 10.1002/cne.20080

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  68 in total

1.  Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain.

Authors:  Prasanth S Ariyannur; John R Moffett; Chikkathur N Madhavarao; Peethambaran Arun; Nisha Vishnu; David M Jacobowitz; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Comp Neurol       Date:  2010-08-01       Impact factor: 3.215

2.  Expression and localization of myosin-1d in the developing nervous system.

Authors:  Andrew E Benesh; Jonathan T Fleming; Chin Chiang; Bruce D Carter; Matthew J Tyska
Journal:  Brain Res       Date:  2012-01-08       Impact factor: 3.252

3.  Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed Cell Death through the TFEB-PUMA Axis.

Authors:  Lu O Sun; Sara B Mulinyawe; Hannah Y Collins; Adiljan Ibrahim; Qingyun Li; David J Simon; Marc Tessier-Lavigne; Ben A Barres
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

4.  The impact of structural biology on neurobiology.

Authors:  Ronald E Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

5.  Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.

Authors:  Stephen Zano; Radhika Malik; Sylvia Szucs; Reuben Matalon; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2010-10-30       Impact factor: 4.797

6.  Early postnatal proteolipid promoter-expressing progenitors produce multilineage cells in vivo.

Authors:  Fuzheng Guo; Joyce Ma; Erica McCauley; Peter Bannerman; David Pleasure
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 7.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

8.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

9.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

10.  Region- and age-dependent alterations of glial-neuronal metabolic interactions correlate with CNS pathology in a mouse model of globoid cell leukodystrophy.

Authors:  Tore Wergeland Meisingset; Alessandra Ricca; Margherita Neri; Ursula Sonnewald; Angela Gritti
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-24       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.